Home › Companies › Rhythm Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Rhythm Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-25 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Rhythm Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Rhythm Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-25 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: David W. J. McGirr | 53,167,971 | -- | -- | 8,704,527 | 2,273,648 | Majority: yes |
| Elect Director: David P. Meeker, MD | 59,961,848 | -- | -- | 1,910,650 | 2,273,648 | Majority: yes |
| Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. | 63,924,852 | 197,701 | 23,593 | -- | 0 | Majority: yes |
| Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | 50,368,659 | 11,467,157 | 36,682 | -- | 2,273,648 | Majority: yes |
Source: Rhythm Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-25 — read the filing on EDGAR.
Each item below shows how the 315 asset managers that disclosed a Rhythm Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 10 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”): 50,368,659 for, 11,467,157 against, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,445,084 outstanding shares: 74% for, 17% against (90% of the company cast a for/against vote).
The 314 asset managers below cast 79% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,814,548 | 1,919 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 6,616,427 | 0 | 0 | 0 | For |
| BlackRock | 5,775,387 | 8,500 | 119 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,604,483 | 0 | 0 | 0 | For |
| Fidelity | 4,196,972 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 3,406,249 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,153,101 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 0 | 3,055,872 | 0 | 0 | Against |
| Federated Hermes | 2,521,147 | 0 | 0 | 0 | For |
| State Street | 2,099,547 | 30,988 | 0 | 0 | For |
| Capital Group | 0 | 1,841,910 | 0 | 0 | Against |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 0 | 1,750,593 | 0 | 0 | Against |
| PERCEPTIVE ADVISORS LLC | 1,505,179 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,412,746 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 1,410,524 | 0 | 0 | Against |
| Janus Henderson | 1,276,610 | 14,502 | 0 | 0 | For |
| Checkpoint Capital L.P. | 1,187,666 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,183,002 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,136,275 | 0 | 0 | 0 | For |
| JPMorgan | 1,081,122 | 0 | 0 | 0 | For |
| Charles Schwab | 1,059,385 | 0 | 0 | 0 | For |
| Putnam | 0 | 990,690 | 0 | 0 | Against |
| Citadel | 881,582 | 0 | 0 | 0 | For |
| Loomis Sayles | 665,762 | 36,978 | 0 | 0 | For |
Showing the 25 largest of 314 asset managers. See all 314 in the interactive database.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Meeker, MD”): 59,961,848 for, 1,910,650 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,445,084 outstanding shares: 88% for, 3% withheld (90% of the company cast a for/withheld vote).
The 83 asset managers below cast 100% of the shares they voted on this item FOR (26,706,633 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,298,341 | 0 | 3,463 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,062,793 | 0 | 10 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 437,490 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 415,259 | 0 | Abstain |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 279,705 | 0 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 141,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 124,948 | 0 | 3,294 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Combines 6 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David W. J. McGirr”): 53,167,971 for, 8,704,527 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,445,084 outstanding shares: 78% for, 13% withheld (90% of the company cast a for/withheld vote).
The 83 asset managers below cast 100% of the shares they voted on this item FOR (24,455,090 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,298,324 | 0 | 3,480 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,053,968 | 0 | 8,835 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 0 | 437,490 | 0 | Abstain |
| Putnam | 0 | 0 | 415,259 | 0 | Abstain |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 283,662 | 0 | Abstain |
| Legg Mason | 275,593 | 0 | 4,112 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 203,950 | 0 | 26,095 | 0 | For |
| Lord Abbett | 0 | 0 | 226,824 | 0 | Abstain |
| Equitable | 79,391 | 0 | 128,685 | 0 | Abstain |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 196,524 | 0 | Abstain |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 152,881 | 0 | Abstain |
| Bridge Builder Trust | 44,584 | 0 | 96,950 | 0 | Abstain |
| Goldman Sachs | 113,058 | 0 | 15,184 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
99.6% Majority: yes · of votes cast
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”): 63,924,852 for, 197,701 against, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,445,084 outstanding shares: 93% for, 0.3% against (94% of the company cast a for/against vote).
The 83 asset managers below cast 99.9% of the shares they voted on this item FOR (27,162,603 for, 31 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,301,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,062,772 | 31 | 0 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 437,490 | 0 | 0 | 0 | For |
| Putnam | 415,259 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 279,705 | 0 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 141,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 128,242 | 0 | 0 | 0 | For |
Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.
Ranked by the number of Rhythm Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 68,445,084 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.96% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.67% |
| 3 | BlackRock | 8.45% |
| 4 | BAKER BROS. ADVISORS LP | 8.19% |
| 5 | Fidelity | 6.13% |
| 6 | PRIMECAP MANAGEMENT CO/CA/ | 4.98% |
| 7 | PRIMECAP Odyssey Funds | 4.70% |
| 8 | T. Rowe Price | 4.61% |
| 9 | Polar Capital Holdings Plc | 4.46% |
| 10 | Federated Hermes | 3.68% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 9.74% | 13G |
| BlackRock | 9.11% | 13F |
| Vanguard Group | 9.07% | 13F |
| PRIMECAP MANAGEMENT CO/CA/ | 5.08% | 13G |
| State Street | 3.32% | 13F |
| Goldman Sachs | 2.87% | 13F |
| FMR (Fidelity) | 2.47% | 13F |
| T. Rowe Price | 2.42% | 13F |
| JPMorgan Chase | 2.27% | 13F |
| Citadel Advisors | 2.12% | 13F |
Percentages above are of 68,445,084 shares outstanding, as reported by Rhythm Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rhythm Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Rhythm Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-24, in the 2025-2026 proxy season, 315 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,666 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — FOR was 81% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Rhythm Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-25.
Rhythm Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).